Curative treatment of prostate cancer with the combination of radiation and hormone therapies

Endocrine-Related Cancer

Volumn 3, Issue 3, 1996, Pages 157-163

  Chuba, P J ^a   Porter, A T ^a   Ben Josef, E ^a   Hart, K ^a   Forman, J D ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; KETOCONAZOLE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NILUTAMIDE; SPIRONOLACTONE;

CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; REVIEW; TREATMENT OUTCOME;

EID: 0029998578     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0030157     Document Type: Review

References (38)

1. Bagshaw MA, Cox RS & Hancock SL 1994 Control of prostate cancer with radiotherapy. Long-term results. Journal of Urology 152 1781-1785.
2. Berges RR, Furuya Y, Remington L, English HF, Jacks T & Isaacs JT 1993 Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proceedings of the National Academy of Sciences of the USA 90 8910-8914.
3. Byar DP 1973 The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 32 1126-1130.
4. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S & Buttyan R 1993 Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory prostate cancers. American Journal of Pathology 143 390-400.
5. Crawford DE & Nabors W 1991 Hormone therapy of advanced prostate cancer. Where we stand today. Oncology 5 21-27.
6. Crawford ED, Eisenberger MA, McLeod, Spaulding JT, Benson R, Dorr A, Blumenstein BA, Davis MA & Goodman PJ 1989 A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New England Journal of Medicine 321 419-424.
7. Dewey WC, Ling CC & Meyn RE 1995 Radiation induced apoptosis: relevance to radiotherapy. International Journal of Radiation Oncology-Biology-Physics 33 781-796.
8. Forman JD, Oppenheim T, Liu H, Montie J, McLaughlin PW & Porter AT 1993a Frequency of residual neoplasm in the prostate following three-dimensional conformal radiotherapy. Prostate 23 235-243.
9. Forman JD, Orton C, Ezzell G & Porter AT 1993b Preliminary results of a hyperfractionated dose escalation study for locally advanced adenocarcinoma of the prostate. Radiotherapy and Oncology 27 203-208.
10. Forman JD, Kumar R, Haas G, Montie J, Porter AT & Mesina CF 1995 Neoadjuvant hormonal downsizing of localized carcinoma of the prostate. Effects on the volume of tissue irradiated. Cancer Investigation 13 8-15.
11. Freiha FS & Bagshaw MA 1994 Carcinoma of the prostate. Results of post-irradiation biopsy. Prostate 5 19-25.
12. Furuya Y, Lin XS, Walsh JC, Nelson WG & Isaacs JT 1995 Androgen ablation-induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle of p53 induction. Endocrinology 136 1898-1906.
13. Gao X, Porter AT & Honn KV 1995a Tumor suppressor genes and their involvement in human prostate cancer. Cancer Molecular Biology 2 475-497.
14. Gao X, Grignon DJ, Chbihi T, Zacharek A, Chen YQ, Sakr W, Porter AT, Crissman JD, Pontes JE & Powell U 1995b Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology 13 461-464.
15. Goldie JH & Coldman AJ 1979 A mathematic model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treatment Reports 63 1727-1733.
16. Gomez JL, Laverdiere J, Cusan L, Suburu ER, Diamond P, Lemay M, Candas B & Labrie F 1995 Beneficial effect of combination antiandrogen blockade prior to and following external beam radiation therapy in localized prostate cancer. International Symposium on Recent Advances in Diagnosis and Treatment of Prostate Cancer, Quebec City, Canada.
17. Green N, Bodner H, Broth E, Chiang C, Garrett J, Goldstein A, Goldberg H, Gualtieri V, Gray R, Jaffe J, Kaplan R, Polse S, Ross S, Skaist L, Treible D, Vatz A & Wallack H 1984 Improved control of bulky prostate carcinoma with sequential estrogen and radiation therapy. International Journal of Radiation Oncology-Biology-Physics 10 971-976.
18. Hanks GE, Leibel SA, Krall JM & Kramer S 1985 Patterns of care studies. Dose-response observations for local control of adenocarcinoma of the prostate. International Journal of Radiation Oncology-Biology-Physics 11 153-157.
19. Hanks GE, Martz KL & Diamond JJ 1988 The effect of dose on local control of prostate cancer. International Journal of Radiation Oncology-Biology-Physics 15 1299-1305.
20. Hanks GE, Asbell S, Krall JM, Perez CA, Doggett S, Rubin P, Sause W & Pilepich MV 1991 Outcome for lymph node dissection negative T-1b, T2 (A-2, B) prostate cancer treated with external beam radiation therapy in RTOG 7706. International Journal of Radiation Oncology-Biology-Physics 21 1099-1103.
21. Hengartner MO 1995 Life and death decisions: ced-9 and programmed cell death in Caenorhabditis elegans. Science 270 930-931.
22. Huggins C & Hodges CL 1941 Studies on prostatic cancer. II. The effect of castration on clinical patients with carcinoma of the prostate. Archives of Surgery 43 209-223.
23. Kuban DA, el-Mahdi AM & Schellhammer PF 1987 Effect of local tumor control on distant metastases and survival in prostate cancer. Urology 30 420-426.
24. Kuban DA, el-Mahdi AM & Schellhammer P 1992 The significance of post-irradiation prostate biopsy with long-term follow-up. International Journal of Radiation Oncology-Biology-Physics 24 409-414.
25. Labrie F, Bélanger A, Dupont A, Luu-The V, Simard J & Labrie C 1993a Science behind total androgen blockade. From gene to combination therapy. Clinical and Investigative Medicine 16 475-492.
26. Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Tetu B, Emond J & Candas B 1993b Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: The first controlled and randomized trial. Clinical and Investigative Medicine 16 499-509.
27. Leibel SA, Heimann R, Kutcher GJ, Zelefsky MJ, Burman CM, Melian E, Orazem JP, Mohan R, LoSasso TJ, Lo YC, Weisberg JA, Chapman DS, Ling CC & Fuks Z 1993 Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate. Preliminary results of a phase I dose-escalation study. International Journal of Radiation Oncology-Biology-Physics 28 55-65.
28. Ling CC, Chen CH & Fuks Z 1994a An equation for the dose response of radiation-induced ptosis. Possible incorporation with the LQ model. Radiotherapy and Oncology 33 17-22.
29. Ling CC, Chen CH & Li WX 1994b Apoptosis induced at different dose rates: Implication for the shoulder region of cell survival curves. Radiotherapy and Oncology 32 129-136.
30. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM & Campbell ML 1992 Expression of the protooncogene bcl-2 in the prostate and its association with the emergence of androgen-independent prostate cancer. Cancer Research 52 6940-6944.
31. Pilepich MV, Krall JM, John MJ, Rubin P, Porter AT, Marcial VA & Martz KL 1989 Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy. Preliminary results of RTOG 83-07. International Journal of Radiation Oncology-Biology-Physics 16 813-817.
32. Pilepich MV, John MJ, Krall JM, McGowan D, Hwang YS & Perez CA 1990 Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and Zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy. American Journal of Clinical Oncology 13 461-464.
33. Pilepich MV, Caplan R, Al-Sarraf M, John M, Doggett RLS, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P, Shipley WU & Cox JD 1993 Phase III trial of hormonal cytoreduction in conjunction with definitive radiotherapy in advanced prostate carcinoma: the emerging role of PSA in the assessment of outcome. International Journal of Radiation Oncology-Biology-Physics 27 Suppl 1 246.
34. Scardino PT, Frankel JM, Wheeler TM, Meacham RB, Huffman GS, Seale C, Wilbanks JH, Easley J & Carlton CE Jr 1986 The prognostic significance of post-irradiation biopsy in patients with prostatic cancer. Journal of Urology 135 510-516.
35. Sells SF, Wood DP Jr, Joshi-Barve SS, Muthukumar S, Jacob RJ, Crist SA, Humphreys S & Rangnekar VM 1994 Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth and Differentiation 5 457-466.
36. Zagars GK, Johnson DE, von Eschenbach AC & Hussey DH 1988 Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate. Long-term results of a prospective randomized study. International Journal of Radiation Oncology-Biology-Physics 14 1085-1091.
37. Zeitman AL & Shipley WU 1993 Randomized trials in loco-regionally confined prostate cancer. Past, present and future. Seminars in Radiation Oncology 3 210-220.
38. Zincke H & Utz DC 1984 Observation on surgical management of carcinoma of the prostate with limited nodal metastases. Urology 24 107.